A Phase 3 clinical trial validating the potency and safety of an innovative, extra‐long‐acting interferon in chronic hepatitis C

A Phase 3 clinical trial validating the potency and safety of an innovative, extra‐long‐acting interferon in chronic hepatitis C

Abstract Background and Aim Ropeginterferon alfa‐2b is a novel mono‐pegylated, extra‐long‐acting interferon. It is administered infrequently and showed good tolerability and clinical activity for the chronic hepatitis B or C treatment in our previous Phase 2 clinical trials. This study aims to valid...

Ful tanımlama

Detaylı Bibliyografya
Asıl Yazarlar: Chi‐Yi Chen, Wan‐Long Chuang, Albert Qin, Wen‐Hua Zhang, Li‐Ying Zhu, Guo‐Qiang Zhang, Jyh‐Jou Chen, Ching‐Chu Lo, Xinmin Zhou, Xiaorong Mao, Jia Shang, Hsing‐Tao Kuo, Wen Xie, Chien‐Hung Chen, Gin‐Ho Lo, Dae W Jun, Shuangsuo Dang, Chan‐Yen Tsai, Ting‐Fang Wang, Hsin‐Hui Lai, Kuan‐Chiao Tseng, Yi‐Wen Huang, Pei‐Jer Chen
Materyal Türü: Makale
Dil:English
Baskı/Yayın Bilgisi: Wiley 2022-11-01
Seri Bilgileri:JGH Open
Konular:
chronic hepatitis B
chronic hepatitis C
chronic hepatitis C genotype 2
chronic viral hepatitis
clinical trial
ropeginterferon alfa‐2b
Online Erişim:https://doi.org/10.1002/jgh3.12825

Internet

https://doi.org/10.1002/jgh3.12825

Benzer Materyaller